Loss of raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC)

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Karamitopoulou, Eva ^a   Zlobec, Inti ^a   Gloor, Beat ^b   Kondi Pafiti, Agathi ^c   Lugli, Alessandro ^a   Perren, Aurel ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Epithelial mesenchymal transition; Pancreatic cancer; RKIP; Tumor buds

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RAS PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PHENOTYPE; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; TISSUE MICROARRAY; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN;

EID: 84889999331     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-311     Document Type: Article

References (38)

1. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, Kolch W. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 2000, 20:3079-3085. 10.1128/MCB.20.9.3079-3085.2000, 85596, 10757792.
2. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999, 401(6749):173-177. 10.1038/43686, 10490027.
3. Wu K, Bonavida B. The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol 2009, 29:241-254. 10.1615/CritRevImmunol.v29.i3.40, 19538137.
4. Tang H, Park S, Sun SC, Trumbly R, Ren G, Tsung E, Yeung KC. RKIP inhibits NF-kappaB in cancer cells by regulating upstream signaling components of the IkappaB ninase complex. FEBS Lett 2010, 584:662-668. 10.1016/j.febslet.2009.12.051, 20043910.
5. Al-Mulla F, Bitar MS, Taqi Z, Yeung KC. RKIP: much more than Raf kinase inhibitory protein. J Cell Physiol 2013, 228:1688-1702. 10.1002/jcp.24335, 23359513.
6. Al-Mulla F. RKIP and cellular motility. J Cell Physiol 2012, 227:2969-2970. 10.1002/jcp.23011, 21898407.
7. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003, 95:878-889. 10.1093/jnci/95.12.878, 12813171.
8. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK. Reduction in raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 2004, 64:5186-5192. 10.1158/0008-5472.CAN-03-3861, 15289323.
9. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, Garcia JJ, Kolch W. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 2005, 11:7392-7397. 10.1158/1078-0432.CCR-05-0283, 16243812.
10. Zlobec I, Baker K, Minoo P, Jass JR, Terracciano L, Lugli A. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion and Raf-1 kinase inhibitor protein expression. Clin Cancer Res 2008, 14:143-148. 10.1158/1078-0432.CCR-07-1380, 18172264.
11. Karamitopoulou E, Lugli A, Patsouris E, Panayiotides I, Karakitsos P, Rallis G, Peros G, Terracciano L, Zlobec I. Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. Histopathology 2010, 57:233-243. 10.1111/j.1365-2559.2010.03615.x, 20716165.
12. Karamitopoulou E, Zlobec I, Panayiotides I, Patsouris E, Peros G, Rallis G, Terracciano L, Lugli A. Systematic analysis of proteins from different signalling pathways in the tumor centre and the invasive front of colorectal cancer. Hum Pathol 2011, 42:1888-1896. 10.1016/j.humpath.2010.06.020, 21664646.
13. Koelzer V, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A. Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. Br J Cancer 2013, 108:2088-2096. 10.1038/bjc.2013.197, 23632477.
14. Hidalgo M. Pancreatic cancer. NEJM 2010, 362:1605-1617. 10.1056/NEJMra0901557, 20427809.
15. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010, 7:163-172. 10.1038/nrclinonc.2009.236, 20101258.
16. Fernandez-del-Castillo C, Jimenez RE, Steer ML. Surgery in the treatment of exocrine pancreas and prognosis. Tanabe KK, http://www.uptodate.com.
17. Li Y, Kong D, Ahmad A, Bao B, Sarkar FH. Pancreatic cancer stem cells: emerging target for designing novel therapy. Cancer Lett 2012, dx.doi.org/10.1016/ j.canlet.2012.03.018.
18. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007, 50:151-162. 10.1111/j.1365-2559.2006.02551.x, 17204028.
19. Brown M, Sillah K, Griffiths EA, Swindell R, West CM, Page RD, Welch IM, Pritchard SA. Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers. Histopathology 2010, 56:893-899. 10.1111/j.1365-2559.2010.03559.x, 20636792.
20. Koike M, Kodera Y, Itoh Y, Nakayama G, Fujiwara M, Hamajima N, Nakao A. Multivariate analysis of the pathologic features of esophageal squamous cell cancer: tumor budding is a significant independent prognostic factor. Annals Surg Oncol 2008, 15:1977-1982.
21. Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y, Nishida T, Mano M, Mori M, Doki Y. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer 2009, 115:3324-3334. 10.1002/cncr.24390, 19452547.
22. Roh MS, Lee JI, Choi PJ. Tumor budding as a useful prognostic marker in esophageal squamous cell carcinoma. Dis Esophagus 2004, 17:333-337. 10.1111/j.1442-2050.2004.00436.x, 15569373.
23. Gabbert H, Wagner R, Moll R, Gerharz CD. Tumor dedifferentiation: an important step in tumor invasion. Clin Exp Metastasis 1985, 3:257-279. 10.1007/BF01585081, 3907917.
24. Gabbert HE, Meier S, Gerharz CD, Hommel G. Tumor-cell dissociation at the invasion front: a new prognostic parameter in gastric cancer patients. Int J Cancer 1992, 50:202-207. 10.1002/ijc.2910500208, 1730514.
25. Ohike N, Coban I, Kim GE, Basturk O, Tajiri T, Krasinskas A, Bandyopadhyay S, Morohoshi T, Shimada Y, Kooby DA, Staley CA, Goodman M, Adsay NV. Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am J Surg Pathol 2010, 34:1417-1424. 10.1097/PAS.0b013e3181f0b05a, 3163902, 20871215.
26. Brabletz T, Spaderna S, Kolb J, Hlubek F, Faller G, Bruns CJ, Jung A, Nentwich J, Duluc I, Domon-Dell C, Kirchner T, Freund JN. Down-regulation of the homeodomain factor Cdx2 in colorectal cancer by collagen type I: an active role for the tumor environment in malignant tumor progression. Cancer Res 2004, 64:6973-6977. 10.1158/0008-5472.CAN-04-1132, 15466189.
27. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009, 119:1417-1419. 10.1172/JCI39675, 2689122, 19487817.
28. Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Patsouris E, Gennatas K, Lykoudis P, Gloor B, Lugli A. Tumor budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer 2013, 49:1032-1039. 10.1016/j.ejca.2012.10.022, 23177090.
29. McShane L, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. For the statistics subcommittee of the NCI-EORTC working group on cancer diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Eur J Cancer 2005, 41:1690-1696. 10.1016/j.ejca.2005.03.032, 16043346.
30. Karamitopoulou E, Zlobec I, Kölzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K, Lugli A. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol 2013, 26:295-301. 10.1038/modpathol.2012.155, 23018875.
31. Perneger TV. Adjusting for multiple testing in studies is less important than other concerns. BMJ 1999, 318(7193):1288.
32. Birner P, Jesch B, Schultheis A, Schoppmann SF. RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its metastases. Clin Exp Metastasis 2012, 29:551-559. 10.1007/s10585-012-9470-8, 22460832.
33. Kim HS, Kim GY, Lim SJ, Kim YW. Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma. Pathology 2010, 42:655-660. 10.3109/00313025.2010.522172, 21080875.
34. Song SP, Zhang SB, Li ZH, Zhou YS, Li B, Bian ZW, Liao QD, Zhang YD. Reduced expression of Raf kinase inhibitor protein correlates with poor prognosis in pancreatic cancer. Clin Transl Oncol 2012, 14:848-852. 10.1007/s12094-012-0870-7, 22855160.
35. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15:416-428. 10.1016/j.ccr.2009.03.016, 2881229, 19411070.
36. Al-Mulla F, Bitar MS, Taqi Z, Rath O, Kolch W. RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol Biosyst 2011, 7(3):928-941. 10.1039/c0mb00208a, 21180766.
37. Al-Mulla F, Bitar MS, Al-Maghrebi M, Behbehani AI, Al-Ali W, Rath O, Doyle B, Tan KY, Pitt A, Kolch W. Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3b. Cancer Res 2011, 71(4):1334-1343. 10.1158/0008-5472.CAN-10-3102, 21303975.
38. Al-Mulla F, Bitar MS, Feng J, Park S, Yeung KC. A new model for raf kinase inhibitory protein induced chemotherapeutic resistance. PLoS One 2012, 7(1):e29532. doi: 10.1371/journal.pone.0029532. Epub 2012 Jan 18, 10.1371/journal.pone.0029532, 3261143, 22279539.